Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchang
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... SAN ANTONIO, July 12, 2011 Sevocity, the ... that Sevocity v11.1 has achieved full certification through ... and is a CCHIT Certified® 2011 Ambulatory EHR. ... usability rating, the highest level awarded by CCHIT. ...
... Surgical Care Affiliates (SCA), a national leader in ... and surgery departments, announced today it has entered into ... subsidiary of Suburban Hospital Healthcare System, Inc., a member ... in the Bethesda and Montgomery County areas. ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... used birth control pills containing high-dose estrogen and a ... cancer, whereas women using some other formulations did not, ... a journal of the American Association for Cancer Research. ... contraceptives [birth control pills] in the past year is ... never or former oral contraceptive use, and that this ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , opened ... Horn Road in Lake Leelanau. Joining the Northern Loop of ... the 25th winery along the trail. The winery will participate ... making its trail event debut during the Harvest Stompede on ... and Faye Mathia opened the boutique winery in the former ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... 28 Dr. Jeffrey Cummings, Medical,Director of The ... the prestigious Ronald and Nancy Reagan Research Award ... themselves to, discovering new,treatments and methods of care ... In his speech of acceptance at the annual ...
... finds molecule boosted cells eliminating colitis, Crohn,s symptoms , , ... by intestinal bacteria can eliminate symptoms of inflammatory bowel ... includes Crohn,s disease and ulcerative colitis. , It ... and other mammals contain about 1,000 different species of ...
... of Pennsylvania School of Medicine have shown how Argos, ... binding growth factors that promote the progression of cancer. ... new drug designs for inhibiting cancer. The study appeared ... Many types of tumors grow because of over-expression of ...
... 300-Page Book, with Foreword by FDA,s Janet Woodcock, ... WASHINGTON, May 28 Now that the Food ... the safe use of,pharmaceuticals, drug manufacturers can be ... their marketing on,existing pharmaceuticals., To help pharmaceutical ...
... DRAXIS Health Inc. ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) ... all of DRAXIS, common shares have been acquired by,an ... common share. As a result, DRAXIS common stock is ... on the Toronto Stock Exchange at,market close on Thursday, ...
... engineer. As a youngster, she had a fascination with ... Today, Sullivan, an assistant professor of chemical engineering at ... applying her knowledge and talents to an area critical ... drugs and gene therapies to diseased and damaged cells ...
Cached Medicine News:Health News:Gut Bacteria Fights Inflammatory Bowel Disease 2Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: